Bristol Improves R&D Benchmark: 80% Of Pre-Clinical Candidates Enter Trials
Executive Summary
Bristol-Myers Squibb has improved its early development success rate to the level that 80% of recommended development candidates make it into human testing, the company said during its R&D update Nov. 17
You may also be interested in...
Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
Bristol Late-Stage Pipeline Reflects Success Of In-House Development
Bristol-Myers Squibb's late-stage pipeline will include 80% internally developed agents, with three of those compounds moving into Phase III
Aventis Drug Candidate Assessment Finds Half Fail Due To Safety Concerns
Almost half of Aventis' new drug candidates fail during development because of safety or toxicity concerns, the drug manufacturer's internal data from 2003 show